«Les études cliniques sont la clé des nouvelles connaissances en termes de diagnostic et de traitement des maladies. Nous sommes fiers d’y contribuer en Suisse.»

Klaudia Georgi, Director Clinical Research MSD Switzerland & Austria

15

médicaments premiers de la classe thérapeutique enregistrés en Suisse depuis 2000

(état: 06/2019)

25

nombre moyen annuel d'études cliniques en Suisse

(état: 06/2019)

80

millons de francs suisses investis dans la recherche depuis 2012

(état: 06/2019)

La recherche clinique de MSD Suisse est coordonnée depuis la filiale de Citybay à Lucerne
Filiales

Le programme d’études cliniques de MSD en Suisse est très diversifié (état: 06/2019)

Etudes clliniques de MSD en cours en Suisse (état: 06/2019)

(publié sur www.clinicaltrials.gov)

Etudes clliniques de MSD en cours en Suisse dans le domaine de l'infectiologie

Étude

Centre d’étude

VIH

MK-1439A-021: A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA™ Once-Daily in Treatment-Naïve HIV-1 Infected

Genève, Lausanne, Zurich

MK-1439A-024: A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

Berne, Lausanne, Zurich

Etudes cliniques de MSD en Suisse dans le domaine de la cardiologie (état: 06/2019)

Étude

Centre d’étude

Insuffisance cardiaque

MK-1242-001 (VICTORIA): A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi-Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects with Heart Failure with Reduced Ejection Fraction (HFrEF) - VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA)

Bâle, Lausanne, Lugano

Etudes cliniques de MSD en Suisse dans le domaine de l'oncologie (état: 06/2019)

Étude

Centre d’étude

Cancer de la prostate

MK-3475-199/KEYNOTE-199: Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Bâle, Coire, Lucerne, Saint-Gall

Cancer de la vessie

MK-3475-676/KEYNOTE-676: A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette-Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HRNMIBC) that is Persistent or Recurrent Following BCG Induction (KEYNOTE-676)

Bâle, Genève, Zurich

Cancer du foie

MK-3475-859/KEYNOTE-937: A phase III adjuvant, randomized, placebo – controlled, double-blinded study, in surgically resected or ablated HCC patients

Basel, Bern, Genf, Lausanne, St.Gallen, Zürich

Cancer du poumon

MK-3475-042/KEYNOTE-042: A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) Versus Platinum Based Chemotherapy in Treatment Naïve Subjects With PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer

Bâle, Berne, Freiburg

MK-3475-495/KEYNOTE-495; KeyImPaCT: A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab-(MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer

Bâle, Coire, Genève, Saint-Gall, Zurich

MK-3475-604/KEYNOTE-604: A Phase 3 Randomized, Double-Blind, Placebo-controlled Trial of Pembrolizumab (MK-3475/SCH900475) in Combination with Etoposide/Platinum (Cisplatin or Carboplatin) for the First-line Treatment of Subjects with Extensive Stage Small Cell Lung Cancer

Coire, Lausanne, Zurich

MK-3475/KEYNOTE-654-04/ECHO-305-04: A Phase 2, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) Plus Epacadostat (INCB024360) Versus Pembrolizumab Plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Berne, Genève, Winterthur, Zurich

MK-3475-859/KEYNOTE-859: A Phase III, randomized, double-blind clinical study of pembrolizumab (MK 3475) plus chemotherapy versus placebo plus chemotherapy as first line treatment in participants with previously untreated, HER2 negative, advanced gastric or gastroesophageal junction adenocarcinoma

Bâle, Bellinzone, Coire, Genève, Lucerne, Saint-Gall, Zurich

Cancer du sein

MK-3475-119/KEYNOTE-119: A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab Versus Single Agent Chemotherapy Per Physician's Choice for Metastatic Triple Negative Breast Cancer (mTNBC)

Bellinzona, Berne, Zurich

Cancer gastrique

MK-3475-062/KEYNOTE-062: A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil Versus Placebo+Cisplatin+5-Fluorouracil as First-Line Treatment in Subjects with Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Bâle, Berne, Coire, Lausanne, Zurich

Carcinome colorectal

MK-3475-177/KEYNOTE-177: A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma

Genève, Zurich

Lymphome à cellules B

MK-3475-170/KEYNOTE 170: A Phase II Study of Pembrolizumab (MK-3475) in Subjects with Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) or Relapsed or Refractory Richter Syndrome (rrRS)

Bellinzona

Mélanome

MK-3475-716/KEYNOTE-716: Adjuvant Therapy with Pembrolizumab Versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study

Bellinzona, Berne, Coire, Genève, Lausanne, Sion, Saint-Gall, Zurich

MK-7902-003: A Phase III, Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) and Lenvatinib (E7080/MK-7902) Versus Pembrolizumab Alone as First-line Intervention in Participants with Advanced Melanoma (LEAP-003)

Bâle, Coire, Lausanne, Zurich

Tumeurs de la tête et du cou

MK-3475-040/KEYNOTE-040: A Phase III Randomized Trial of MK-3475 (Pembrolizumab) versus Standard Treatment in Subjects with Recurrent or Metastatic Head and Neck Cancer

Berne, Genève, Lucerne

MK-3475-048/KEYNOTE-048: A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Bâle, Zurich

MK-3475-689/KEYNOTE-689: A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)

Bellinzone, Genève, Zurich

Tumeurs solides avancées

MK-3475-587/KEYNOTE-587: Long-term Safety and Efficacy Extension Study for Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study

Zurich

MK-7339-002: A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer

Bellinzone, Genève, Zurich

MK-8353-014: Phase 1 b Open-label Study of MK-8353 in Combination with Selumetinib (MK-5618) in Participants with Advanced/Metastatic Solid Tumors

Bellinzone

Vers l’aperçu des études en Suisse, rechercher les participants www.kofam.ch

Nous aimerions redonner espoir aux personnes victimes d’un cancer

Nous investissons dans le développement de médicaments oncologiques innovateurs pour aider les personnes victimes d’une maladie cancéreuse.

En savoir plus

CH-NON-00136, 06/2019